Results 101 to 110 of about 499,109 (301)

The impact of pharmacogenetic‐informed care on medication adherence and psychological factors associated with adherence: A narrative review

British Journal of Clinical Pharmacology, EarlyView.
Improvement in medication adherence is often proposed as a potential advantage of pharmacogenetic‐guided prescribing over a traditional one‐size‐fits‐all approach. This paper provides a review of the published literature and presents the findings of studies that measure adherence to medication as an outcome of pharmacogenetic‐informed care, or that ...
Lucy Galloway, Alison Wright, John Weinman   +2 more
wiley   +1 more source

Pharmacokinetics and safety of a modified‐release psilocybin formulation: A SAD Phase I trial in normal‐weight and overweight/obese participants

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to evaluate the safety, tolerability and pharmacokinetics of a novel oral modified‐release psilocybin formulation (REL‐P11) in normal‐weight and overweight/obese healthy adults and to assess its suitability for controlled, subperceptual exposure, in light of emerging evidence supporting serotonergic modulation in metabolic ...
Anna Signor, Stefano Comai, Gianfranco Pasut, Franco Folli, Marco Gentilucci, Negar Gharavi, Sofia Raitsin, Thuy Van Nguyen, Marco Pappagallo, Andrea Mattarei, Paolo L. Manfredi, Sara De Martin   +11 more
wiley   +1 more source

Experiences of Prisoners Living With Mental Health Conditions and Seeking or Receiving Mental Health Support in Prisons: An Integrative Review

Criminal Behaviour and Mental Health, EarlyView.
ABSTRACT Background Prisoners experience poor mental health and well‐being in prison, including severe mental illnesses. However, access to mental health support and treatment in prison is limited. We conducted an integrative review to synthesise prisoners' experiences of living with mental ill health and/or seeking or receiving mental health support ...
Anne Kairu, Judith Dyson, Damian Breen, James Skinner, Manuela Jarrett, Joanne Brooke   +5 more
wiley   +1 more source

Novel Psychoactive Substances: important information for health professionals.

, 2017
Novel psychoactive substances (NPS; also known as new psychoactive substances or popularly, although erroneously, as ‘legal highs’) is the name given to drugs that are newly synthesised or newly available, and which do not fall under the control of ...
Hamilton, Ian, Monaghan, Mark, Sumnall, Harry   +2 more
core  

How to Optimize Healthy Volunteer Screening and Enrolment in Clinical Trials: A Qualitative and Quantitative Approach to Evaluate Processes and Healthy Volunteers' Perceptions

Clinical Pharmacology &Therapeutics, EarlyView.
Healthy volunteers (HVs) are essential for phase I trials, yet their recruitment and screening remain resource‐intensive and ethically complex. High screening failure (SF) rates highlight the need to evaluate and understand all aspects of the enrolment processes. We analyzed SF patterns in a large German HV cohort and explored participants' motivations,
Evelyn Krohmer, Manuela König, Cathrin J. Vogt, Marina Streckebein, Sybille Baumann, Max Blumenstock, Ruwen Böhm, Fabian Müller, Nadja Struß, Viktoria S. Wurmbach, Antje Blank   +10 more
wiley   +1 more source

Council and Parliament agree on new mechanism to better protect Europeans from new psychoactive substances.

, 2017
On 29 May, the Council and the Parliament reached a political agreement on a package reforming the legislation on new psychoactive substances (NPS) used as alternatives to illicit drugs.

core  

Understanding Consumption of Illicit Drugs and New Psychoactive Substances in Australia by Triangulating Drug Checking and Wastewater‐Based Epidemiology

Drug Testing and Analysis, Volume 18, Issue 10, Page 1244-1255, October 2026.
First Australian study combining wastewater‐based epidemiology and drug checking, demonstrating how complementary data sources enhance monitoring of illicit drugs and emerging psychoactive substances during high‐use periods. ABSTRACT Consumption of psychotropic drugs is a major economic and public health challenge in Australia.
Muhammad Usman, Malcolm McLeod, Dhayaalini Nadarajan, Joseph Clokey, Pritesh Prasad, Rory Verhagen, Benjamin Tscharke, Maurizio Quinto, Richard Bade   +8 more
wiley   +1 more source

Micro‐QuEChERS Extraction for Broad‐Spectrum LC‐QQQ‐MS Quantification of Nitazene Analogs in Plasma: A Validated Method With Casework Application

Drug Testing and Analysis, Volume 18, Issue 10, Page 1296-1310, October 2026.
Micro‐QuEChERS sample preparation coupled to LC‐QQQ‐MS enabled sensitive quantification of nitazene analogs in 100 μL of plasma. The validated method provided low detection limits and was successfully applied to an authentic intoxication case involving N‐pyrrolidino protonitazene, supporting clinical and forensic toxicology workflows.
Karla A. O. Souza, Náthaly C. B. F. Santos, Rafael Lanaro, Sara E. Walton, Alex J. Krotulski, Barry K. Logan, Mauricio Yonamine, Jose Luiz Costa   +7 more
wiley   +1 more source

Novel psychoactive substances: synthetic cannabinoids - best practice treatment approaches.

, 2017
The use of new psychoactive substances [NPS] in prisons has been recognised as an increasing problem for several years. Successive Chief Inspectors of Prisons and the Prisons and Probation Ombudsman in the UK have drawn attention to the impact on prisons,
Ryan, George
core  

Antidepressant Misuse in Esports: A Review of Pharmacology, Adverse Effects, Pharmacokinetics and Biomatrix‐Based Detection for Anti‐Doping Applications

Drug Testing and Analysis, EarlyView.
This review highlights the misuse of antidepressants as potential cognitive‐enhancing agents in Esports. Despite pharmacological effects that overlap with those of psychostimulants, antidepressants remain an under‐recognised source of doping in Esports.
Kassim Ali Salum, Shao‐Hsin Hung, Meng‐Tsang Hsieh, Mei‐Chich Hsu, William Chih‐Wei Chang   +4 more
wiley   +1 more source